191 related articles for article (PubMed ID: 37444393)
1. Pro-Gastrin-Releasing Peptide as a Biomarker in Lung Neuroendocrine Neoplasm.
Rosiek V; Kogut A; Kos-Kudła B
Cancers (Basel); 2023 Jun; 15(13):. PubMed ID: 37444393
[TBL] [Abstract][Full Text] [Related]
2. Pro-gastrin-releasing peptide, neuron specific enolase and chromogranin A as serum markers of small cell lung cancer.
Lamy PJ; Grenier J; Kramar A; Pujol JL
Lung Cancer; 2000 Sep; 29(3):197-203. PubMed ID: 10996422
[TBL] [Abstract][Full Text] [Related]
3. The prognostic significance of circulating neuroendocrine markers chromogranin a, pro-gastrin-releasing peptide and neuron-specific enolase in patients with advanced non-small-cell lung cancer.
Nisman B; Heching N; Biran H; Barak V; Peretz T
Tumour Biol; 2006; 27(1):8-16. PubMed ID: 16340245
[TBL] [Abstract][Full Text] [Related]
4. [Establishment of cut-off value of serum pro-gastrin-releasing peptide for diagnosis of small cell lung cancer and evaluation on the clinical diagnosis efficiency].
Shen D; Han BB; Chen F; Wei BJ; Cui CJ; Wang GJ; Cui W
Zhonghua Yi Xue Za Zhi; 2017 Sep; 97(34):2657-2662. PubMed ID: 28910952
[No Abstract] [Full Text] [Related]
5. Prospective Evaluation of the NETest as a Liquid Biopsy for Gastroenteropancreatic and Bronchopulmonary Neuroendocrine Tumors: An ENETS Center of Excellence Experience.
Malczewska A; Witkowska M; Wójcik-Giertuga M; Kuśnierz K; Bocian A; Walter A; Rydel M; Robek A; Pierzchała S; Malczewska M; Leś-Zielińska I; Czyżewski D; Ziora D; Pilch-Kowalczyk J; Zajęcki W; Kos-Kudła B
Neuroendocrinology; 2021; 111(4):304-319. PubMed ID: 32335553
[TBL] [Abstract][Full Text] [Related]
6. The prognostic significance of the circulating neuroendocrine markers chromogranin A, pro-gastrin-releasing peptide, and neuron-specific enolase in patients with small-cell lung cancer.
Petrović M; Bukumirić Z; Zdravković V; Mitrović S; Atkinson HD; Jurišić V
Med Oncol; 2014 Feb; 31(2):823. PubMed ID: 24375395
[TBL] [Abstract][Full Text] [Related]
7. Blood Chromogranin A Is Not Effective as a Biomarker for Diagnosis or Management of Bronchopulmonary Neuroendocrine Tumors/Neoplasms.
Matar S; Malczewska A; Oberg K; Bodei L; Aslanian H; Lewczuk-Myślicka A; Filosso PL; Suarez AL; Kolasińska-Ćwikła A; Roffinella M; Kos-Kudła B; Ćwikła JB; Drozdov IA; Kidd M; Modlin IM
Neuroendocrinology; 2020; 110(3-4):185-197. PubMed ID: 30995665
[TBL] [Abstract][Full Text] [Related]
8. An elevated progastrin-releasing peptide level in patients with well-differentiated neuroendocrine tumours indicates a primary tumour in the lung and predicts a shorter survival.
Korse CM; Taal BG; Bonfrer JMG; Vincent A; van Velthuysen ML; Baas P
Ann Oncol; 2011 Dec; 22(12):2625-2630. PubMed ID: 21415235
[TBL] [Abstract][Full Text] [Related]
9. Progastrin-releasing peptide as a diagnostic and therapeutic biomarker of small cell lung cancer.
Oh HJ; Park HY; Kim KH; Park CK; Shin HJ; Lim JH; Kwon YS; Oh IJ; Kim YI; Lim SC; Kim YC; Kim SH; Shin MG
J Thorac Dis; 2016 Sep; 8(9):2530-2537. PubMed ID: 27747005
[TBL] [Abstract][Full Text] [Related]
10. Clinical Application of Pro-Gastrin-Releasing Peptide.
Fang L; Huang Z; Lin Y; Fu J; Liang X; Liu F
Clin Lab; 2018 Jul; 64(7):1259-1268. PubMed ID: 30146822
[TBL] [Abstract][Full Text] [Related]
11. Selective application of neuroendocrine markers in the diagnosis and treatment of small cell lung cancer.
Du J; Li Y; Wang L; Zhou Y; Shen Y; Xu F; Chen Y
Clin Chim Acta; 2020 Oct; 509():295-303. PubMed ID: 32592711
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of pro-gastrin releasing peptide promotes the cell proliferation and progression in small cell lung cancer.
Gong Z; Lu R; Xie S; Jiang M; Liu K; Xiao R; Shen J; Wang Y; Guo L
Biochem Biophys Res Commun; 2016 Oct; 479(2):312-318. PubMed ID: 27639644
[TBL] [Abstract][Full Text] [Related]
13. An Assessment of Circulating Chromogranin A as a Biomarker of Bronchopulmonary Neuroendocrine Neoplasia: A Systematic Review and Meta-Analysis.
Malczewska A; Kidd M; Matar S; Kos-Kudła B; Bodei L; Oberg K; Modlin IM
Neuroendocrinology; 2020; 110(3-4):198-216. PubMed ID: 31266019
[TBL] [Abstract][Full Text] [Related]
14. Triple test with tumor markers CYFRA 21.1, HE4, and ProGRP might contribute to diagnosis and subtyping of lung cancer.
Korkmaz ET; Koksal D; Aksu F; Dikmen ZG; Icen D; Maden E; Onder S; Akbiyik F; Emri S
Clin Biochem; 2018 Aug; 58():15-19. PubMed ID: 29729229
[TBL] [Abstract][Full Text] [Related]
15. Plasma proGRP concentration is sensitive and specific for discriminating small cell lung cancer from nonmalignant conditions or non-small cell lung cancer.
Kim HR; Oh IJ; Shin MG; Park JS; Choi HJ; Ban HJ; Kim KS; Kim YC; Shin JH; Ryang DW; Suh SP
J Korean Med Sci; 2011 May; 26(5):625-30. PubMed ID: 21532852
[TBL] [Abstract][Full Text] [Related]
16. Pro-Gastrin-Releasing Peptide as a Marker of Small Cell Lung Cancer.
Lyubimova NV; Kuz'minov AE; Markovich AA; Lebedeva AV; Timofeev YS; Stilidi IS; Kushlinskii NE
Bull Exp Biol Med; 2022 Jun; 173(2):257-260. PubMed ID: 35737164
[TBL] [Abstract][Full Text] [Related]
17. Pro-gastrin-releasing peptide in patients with benign and malignant diseases.
Molina R; Auge JM; Alicarte J; Filella X; Viñolas N; Ballesta AM
Tumour Biol; 2004; 25(1-2):56-61. PubMed ID: 15192313
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of chemiluminescent immunoassay quantitative detection for pro-gastrin-releasing peptide (ProGRP) in serum and plasma.
Cheng Y; He J; Zhang L; Chen X; Ou S
J Int Med Res; 2020 Apr; 48(4):300060519882802. PubMed ID: 31856626
[TBL] [Abstract][Full Text] [Related]
19. New and old biomarkers in the differential diagnosis of lung cancer: Pro-gastrin-releasing peptide in comparison with neuron-specific enolase, carcinoembryonic antigen, and CYFRA 21-1.
Mauro C; Passerini R; Spaggiari L; Galetta D; Radice D; Lentati P; Sandri MT
Int J Biol Markers; 2019 Jun; 34(2):163-167. PubMed ID: 30994045
[TBL] [Abstract][Full Text] [Related]
20. Pro-gastrin-releasing peptide (proGRP) in patients with benign and malignant diseases: comparison with CEA, SCC, CYFRA 21-1 and NSE in patients with lung cancer.
Molina R; Auge JM; Filella X; Viñolas N; Alicarte J; Domingo JM; Ballesta AM
Anticancer Res; 2005; 25(3A):1773-8. PubMed ID: 16033098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]